A boost in biosimilars sales provided only minor consolation to Biogen in 2020, as generic competition to its blockbuster Tecfidera (dimethyl fumarate) multiple sclerosis brand in the US late in the year took a bite out of the company’s annual sales, which fell by 6% to $13.4bn.
Biosimilars Rise Is Cold Comfort For Biogen As Tecfidera Competition Bites
Signals ‘Financial Reset’ In 2021 Due To Dimethyl Fumarate Generics
Biosimilars sales rising by 8% to almost $800m in 2020 failed to offset the impact on Biogen of generic competition to its Tecfidera brand in the US.
More from Earnings
• By
Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.
• By
Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.
• By
With sales and profits shooting up in 2024, Alvotech has revealed plans to rapidly accelerate development to add between four and six programs to its pipeline of biosimilars every year, while at the same time unveiling details of several new brands that it will be seeking to challenge. The firm has also set out longer-term financial targets that anticipate more than trebling its revenues in the next three years.
• By
The Chinese player reported its second profitable year in a row, with growth in sales reported across its marketed portfolio and further milestones in the near future.